ื”ืขื“ืคืชื›ื ืขื•ื“ื›ื ื” ืขื‘ื•ืจ ื”ืžืคื’ืฉ ื”ื–ื”. ื›ื“ื™ ืœืฉื ื•ืช ืืช ื”ื’ื“ืจืช ื”ื—ืฉื‘ื•ืŸ ืœืฆืžื™ืชื•ืช, ืขื‘ืจื• ืืœ
ืœื”ื–ื›ื™ืจื›ื, ื ื™ืชืŸ ืœืขื“ื›ืŸ ืืช ื”ืžื“ื™ื ื” ืื• ื”ืฉืคื” ื”ืžื•ืขื“ืคื•ืช ืขืœื™ื›ื ื‘ื›ืœ ืขืช ื‘
> beauty2 heart-circle sports-fitness food-nutrition herbs-supplements pageview
לחצו להצגת הצהרת הנגישות שלנו

7 יתרונות של NAD שנחקרו — מהזדקנות בריאה ועד שיפור רמות האנרגיה

224,615 צפיות

anchor-icon תוכן העניינים dropdown-icon
anchor-icon תוכן העניינים dropdown-icon

ืžื”ื• NAD (ื ื™ืงื•ื˜ื™ืŸ-ืืžื™ื“ ืื“ื ื™ืŸ ื“ื™-ื ื•ืงืœืื•ื˜ื™ื“)?

NAD (ื ื™ืงื•ื˜ื™ืŸ-ืืžื™ื“ ืื“ื ื™ืŸ ื“ื™-ื ื•ืงืœืื•ื˜ื™ื“) ื”ื•ื ืงื•-ืื ื–ื™ื ื”ืžืฆื•ื™ ื‘ื›ืœ ื”ืชืื™ื ื”ื—ื™ื™ื ืฉืžืขื ื™ืง ืžื’ื•ื•ืŸ ื™ืชืจื•ื ื•ืช ื‘ืจื™ืื•ืชื™ื™ื ื‘ืจืžื” ื”ืชืื™ืช ื•ื”ื”ื•ืœื™ืกื˜ื™ืช. 

ืชื•ืกืคื™ NAD ืžืขืœื™ื ืืช ืจื™ื›ื•ื– NAD+ ื‘ื“ื, ืžืฉื ื”ื•ื ื ืกืคื’ ืขืœ-ื™ื“ื™ ื”ืชืื™ื. ืงื•-ืื ื–ื™ื ื–ื” ืžืชื•ื•ืš ืžืกืคืจ ืชื”ืœื™ื›ื™ื ืคื™ื–ื™ื•ืœื•ื’ื™ื™ื, ื›ื•ืœืœ ื—ื™ืœื•ืฃ ื”ื—ื•ืžืจื™ื, ื™ื™ืฆื•ืจ ื”ืื ืจื’ื™ื” ื•ื ื™ืฆื•ืœ ื”ืื ืจื’ื™ื”.

ื”ื”ื‘ื“ืœ ื‘ื™ืŸ NAD+ ืœ-NADH

ืงื™ื™ืžื•ืช ื‘ื’ื•ืฃ ืฉืชื™ ืฆื•ืจื•ืช ืฉืœ NAD, ื•ื”ืŸ NAD+ ื•-NADH. NAD+ ื”ื™ื ื”ืฆื•ืจื” ื”ืžื—ื•ืžืฆื ืช, ื•ืื™ืœื• NADH ื”ื™ื ื”ืฆื•ืจื” ื”ืžื—ื•ื–ืจืช, ื›ืœื•ืžืจ ืžื—ื•ื‘ืจืช ืืœื™ื” ืžื•ืœืงื•ืœืช ืžื™ืžื™ืŸ.

NAD+ ื™ื›ื•ืœื” ืœืงื‘ืœ ืืœืงื˜ืจื•ืŸ, ื•ืื™ืœื• NADH ื”ื™ื NAD ืฉื›ื‘ืจ ืกื™ืคื—ื” ืืœืงื˜ืจื•ืŸ (ื‘ืฆื•ืจื” ืฉืœ ืžื™ืžืŸ).

ื”ื”ืฉืคืขื•ืช ืฉืœ ืžื—ืกื•ืจ ื‘-NAD

ื”ื™ื™ืฆื•ืจ ืฉืœ ืงื•-ืื ื–ื™ื ื–ื” ืคื•ื—ืช ื‘ื”ื“ืจื’ื” ืขื ื”ื’ื™ืœ. ื‘ื”ืชืื ืœื›ืš, ืœืขืชื™ื ืงืจื•ื‘ื•ืช ืžืชืคืชื— ืžื’ื•ื•ืŸ ืฉืœ ืชืกืžื™ื ื™ื ื•ืกื™ืžื ื™ื. ืืžื ื ื”ื™ืจื™ื“ื” ื”ื–ื• ื”ื™ื ื˜ื‘ืขื™ืช ื•ืฆืคื•ื™ื”, ืื‘ืœ ืื™ืŸ ืกืคืง ืฉื”ื™ื ืžืฉืคื™ืขื” ืขืœ ืชื”ืœื™ื›ื™ื ืจื‘ื™ื ื‘ื’ื•ืฃ. ืขืœ ื›ืŸ, ื ื™ืกื™ื•ืŸ ืœืžื˜ื‘ ืืช ืจืžืช ื”-NAD ื‘ื“ื ืขืฉื•ื™ ืœื”ื•ืขื™ืœ ืœื‘ืจื™ืื•ืช ื•ืœืจื•ื•ื—ื” ื”ื›ืœืœื™ืช.

ืชื—ื ื•ืช ื”ื›ื•ื— ืฉืœ ื”ืชืื™ื ืฉืœื ื• (ื›ืœื•ืžืจ ื”ืžื™ื˜ื•ื›ื•ื ื“ืจื™ื”) ืื™ื ืŸ ืžืชืคืงื“ื•ืช ื›ื ื“ืจืฉ ืœืœื NAD. ื›ืชื•ืฆืื” ืžื›ืš, ื™ื›ื•ืœืช ื”ืชืื™ื ืฉืœื ื• ืœื™ื™ืฆืจ ATP (ืื ืจื’ื™ื”) ื ืคื’ืขืช. ืื“ื ืขื ืื‘ืจื•ื ื™ ืžื™ื˜ื•ื›ื•ื ื“ืจื™ื” ื‘ืจื™ืื™ื ืฉืžื™ื™ืฆืจื™ื ATP (ืื ืจื’ื™ื”) ื”ื•ื ื›ืžื• "ืกืžืืจื˜ืคื•ืŸ ืขื ืกื•ืœืœื” ื”ื˜ืขื•ื ื” ื‘ืžืืช ื”ืื—ื•ื–ื™ื", ื–ื” ืžืืคืฉืจ ืœืื“ื ืœืขืฉื•ืช ื™ื•ืชืจ ื‘ืžื”ืœืš ื”ื™ื•ื. ืขื ื–ืืช, ื›ื›ืœ ืฉื”ื˜ืœืคื•ืŸ ื™ืฉืŸ ื™ื•ืชืจ, ื›ืš ื”ืกื•ืœืœื” ืฉืœื• ืžืชืจื•ืงื ืช ืžื”ืจ ื™ื•ืชืจ. ื”ืชืื™ื ืฉืœื ื• ืื™ื ื ืฉื•ื ื™ื ืžืกื•ืœืœืช ื˜ืœืคื•ืŸ.   

ืœืคื™ ืžืกืคืจ ืžื—ืงืจื™ื, ื™ืจื™ื“ื” ื‘ืจืžืช ื”-NAD ืขืœื•ืœื” ืœื”ื•ื•ืช ื˜ืจื™ื’ืจ ื—ื–ืง ืœืฉื•ืจื” ืฉืœ ืžื—ืœื•ืช, ื›ื•ืœืœ ืžื—ืœื•ืช ืœื‘, ืฉื™ื˜ื™ื•ืŸ ื•ื‘ืขื™ื•ืช ืžื˜ื‘ื•ืœื™ื•ืช, ื›ืžื• ืกื•ื›ืจืช ื•ื”ืฉืžื ืช ื™ืชืจ.

ืชื•ืกืคื™ NAD ื™ื›ื•ืœื™ื ืœื”ืขืœื•ืช ืืช ืจืžืช ื”ืงื•-ืื ื–ื™ื ื”ื–ื” ื‘ื“ื ื•ื‘ืชืื™ื ื•ืœืชืจื•ื ืœืฉืžื™ืจื” ืขืœ ื‘ืจื™ืื•ืช ื˜ื•ื‘ื” ื‘ืชื”ืœื™ืš ื”ื”ื–ื“ืงื ื•ืช.

ืžื”ื• NMN (ื ื™ืงื•ื˜ื™ืŸ-ืืžื™ื“ ืžื•ื ื•-ื ื•ืงืœืื•ื˜ื™ื“)?

ื ื™ืงื•ื˜ื™ืŸ-ืืžื™ื“ ืžื•ื ื•-ื ื•ืงืœืื•ื˜ื™ื“ ืื• NMN ื”ื•ื ื—ืœืง ืžืžืฉืคื—ื” ื’ื“ื•ืœื” ืฉืœ ื ื•ืงืœืื•ื˜ื™ื“ื™ื, ืžื•ืœืงื•ืœื•ืช ื”ืžืฆื•ื™ื•ืช ื‘ืžื–ื•ืŸ ืฉืœื ื•. ื”ื•ื ืชื—ื™ืœืŸ ืฉืœ NAD, ื›ืœื•ืžืจ ืœืื—ืจ ื ื˜ื™ืœืช NMN ื”ื’ื•ืฃ ืžื™ื™ืฆืจ ืžืžื ื• NAD.  

ื‘ื“ื•ืžื” ืœื ื•ืงืœืื•ื˜ื™ื“ื™ื ืื—ืจื™ื, NMN ืžื•ืจื›ื‘ ืžืฉืœื•ืฉื” ื—ืœืงื™ื:

  • ื‘ืกื™ืก ื—ื ืงื ื™
  • ืงื‘ื•ืฆืช ืคื•ืกืคื˜  
  • ื•ืžื•ืœืงื•ืœืช ืกื•ื›ืจ ืื—ืช

ืขื ื–ืืช, ื‘ื ื™ื’ื•ื“ ืœื ื•ืงืœืื•ื˜ื™ื“ื™ื ื”ืื—ืจื™ื, ื”ืžื˜ืจื” ื”ืขื™ืงืจื™ืช ืฉืœ NMN ื”ื™ื ืœื™ื™ืฆืจ ื ื™ืงื•ื˜ื™ืŸ-ืืžื™ื“ ืื“ื ื™ืŸ ื“ื™-ื ื•ืงืœืื•ื˜ื™ื“ (NAD). ืœื›ืŸ, ืžืื—ืจ ืฉ-NMN ื”ื•ื ืชื—ื™ืœืŸ ืฉืœ NAD, ืื™ืŸ ืฆื•ืจืš ืœื™ื˜ื•ืœ ื’ื ืชื•ืกืฃ ืฉืœ NMN ื•ื’ื ืชื•ืกืฃ ืฉืœ NAD.

ื–ื›ืจื• ื›ื™ ื”ืจืžื•ืช ืฉืœ NAD ื•-NMN ื™ื•ืจื“ื•ืช ื‘ื”ืชืžื“ื” ื›ื›ืœ ืฉืื ื—ื ื• ืžื–ื“ืงื ื™ื. ื›ืชื•ืฆืื” ืžื›ืš, ืืกืคืงื” ื™ืฉื™ืจื” ืฉืœ NMN ืื• NAD ืขืฉื•ื™ื” ืœื”ืขืœื•ืช ืืช ืจืžืช ื”-NAD ื‘ื’ื•ืฃ.  

ื‘ืžื—ืงืจ ื‘ื• ื”ืฉืชืชืคื•ืช 10 ื’ื‘ืจื™ื ืžื™ืคืŸ, ื”ื—ื•ืงืจื™ื ืžืฆืื• ื›ื™ ืชื•ืกืคื™ NMN ื”ื‘ื™ืื• ืœืขืœื™ื™ื” ืžืฉืžืขื•ืชื™ืช ื‘ืจืžื•ืช ื”-NAD ื‘ื“ื, ืžื” ืฉืžืืฉืฉ ืืช ื”ืชื•ืขืœืช ืฉืœ ื ื˜ื™ืœืช ืชื•ืกืคื™ื. 

ืจื•ื‘ื ื”ืžื›ืจื™ืข ืฉืœ ืชื•ืกืคื™ NAD ืžื›ื™ืœื™ื ืื—ื“ ืžืชื—ื™ืœื ื™ NAD. ื”ืชื—ื™ืœื ื™ื ื”ืœืœื• ืžื•ืžืจื™ื ืœ-NAD ื‘ืขื–ืจืช ืื ื–ื™ืžื™ื ืกืคืฆื™ืคื™ื™ื. 

ื‘ื™ืŸ ื”ืชื—ื™ืœื ื™ื ื”ื ืคื•ืฆื™ื ืฉืœ NAD ื‘ื”ื ืžืฉืชืžืฉื™ื ื‘ื™ื™ืฆื•ืจ ืชื•ืกืคื™ ืชื–ื•ื ื”:

  • ื ื™ืงื•ื˜ื™ืŸ-ืืžื™ื“ ืžื•ื ื•-ื ื•ืงืœืื•ื˜ื™ื“ (NMN)
  • ื ื™ืงื•ื˜ื™ืŸ-ืืžื™ื“ ืจื™ื‘ื•ื–ื™ื“ (NR)
  • ื—ื•ืžืฆื” ื ื™ืงื•ื˜ื™ื ื™ืช (NA)
  • ื ื™ืงื˜ื™ืŸ-ืืžื™ื“ (NAM)
  • ื ื™ืงื•ื˜ื™ืŸ-ืืžื™ื“ ืคื•ืกืคื•-ืจื™ื‘ึผื•ึนื–ื™ืœ-ื˜ืจื ืกืคืจืื– (NAMPT)

ืชืื™ ื”ื’ื•ืฃ ืžืฉืชืžืฉื™ื ื‘ืžืจื›ื™ื‘ื™ื ืžืจื•ื‘ื™ื ื›ื“ื™ ืœื™ื™ืฆืจ NAD. ื‘ื™ื ื™ื”ื ื—ื•ืžืฆื•ืช ืืžื™ื ื•, ื›ืžื• ื˜ืจื™ืคื˜ื•ืคืŸ ื•ื—ื•ืžืฆื” ืืกืคืจื˜ื™ืช, ื•ื’ื ื•ื™ื˜ืžื™ื ื™ื (ืœืžืฉืœ, ื ื™ืืฆื™ืŸ ืื• ื•ื™ื˜ืžื™ืŸ B3). ืจื•ื‘ ื”ืžืจื›ื™ื‘ื™ื ื”ืœืœื• ืžืฆื•ื™ื™ื ื‘ืžื–ื•ืŸ. ืœื›ืŸ, ืชื–ื•ื ื” ื‘ืจื™ืื” ื—ื™ื•ื ื™ืช ืœืฉืžื™ืจื” ืขืœ ื”ื‘ืจื™ืื•ืช ื”ื›ืœืœื™ืช.

ืžืงื•ืจื•ืช ืชื–ื•ื ืชื™ื™ื ืฉืœ NAD

ื ื™ืชืŸ ืœืžืฆื•ื ืืช NMN, ืชื—ื™ืœืŸ ืฉืœ NAD, ื‘ืฉื•ืจื” ืฉืœ ืžื–ื•ื ื•ืช, ื›ื•ืœืœ

  • ืื‘ื•ืงื“ื• โ€“ ืขื“ 1.60 ืž"ื’ ืœ-100 ื’ืจ'
  • ื‘ืจื•ืงื•ืœื™ โ€“ ืขื“ 1.12 ืž"ื’ ืœ-100 ื’ืจ'
  • ื›ืจื•ื‘ โ€“ ืขื“ 0.9 ืž"ื’ ืœ-100 ื’ืจ'
  • ื‘ืฉืจ ื‘ืงืจ ื ื โ€“ ืขื“ 0.42 ืž"ื’ ืœ-100 ื’ืจ'
  • ืขื’ื‘ื ื™ื•ืช โ€“ ืขื“ 0.30 ืž"ื’ ืœ-100 ื’ืจ'

ื’ื ืžืœืคืคื•ื ื™ื, ืื“ืžืžื”, ื“ื’ื™ื, ื‘ืฉืจ ืขื•ืฃ ื•ื—ืœื‘ ืคืจื” ืžื›ื™ืœื™ื NMN.

1. ื”ื–ื“ืงื ื•ืช ื‘ืจื™ืื”

ื”ื”ืฉืคืขื” ื”ื‘ื•ืœื˜ืช ื‘ื™ื•ืชืจ ืฉืœ NAD ื”ื™ื ื”ืื˜ื” ืฉืœ ืชื”ืœื™ืš ื”ื”ื–ื“ืงื ื•ืช ื•ืฉืœ ื”ืชืคืชื—ื•ืช ื”ื”ืคืจืขื•ืช ื”ื ืงืฉืจื•ืช ืืœื™ื•. ืœืคื™ ื“ื™ื•ื•ื™ื“ ืกื™ื ืงืœื™ื™ืจ, ื’ื ื˜ื™ืงืื™ ืžืื•ื ื™ื‘ืจืกื™ื˜ืช ื”ืจื•ื•ืืจื“, ื”ืขืœืืช ืจืžื•ืช NAD ื‘ื“ื ื•ื‘ืชืื™ื ืขืฉื•ื™ื” ืœื”ืื˜ ืืช ืชื”ืœื™ืš ื”ื”ื–ื“ืงื ื•ืช. 

ื ืจืื” ื›ื™ NAD ืžืื˜ ืืช ืชื”ืœื™ืš ื”ื”ื–ื“ืงื ื•ืช ื‘ืืžืฆืขื•ืช ืžืกืคืจ ืžื ื’ื ื•ื ื™ื:

ืจืืฉื™ืช, ื™ื“ื•ืข ืฉื”ื˜ืœื•ืžืจื™ื ืžืชืงืฆืจื™ื ื›ื›ืœ ืฉืื ื• ืžื–ื“ืงื ื™ื. ื˜ืœื•ืžืจื™ื ื”ื ืจืฆืคื™ื ืฉืœ ืงื•ื“ื™ ื“ื "ื ื—ื•ื–ืจื™ื ื‘ืงืฆื•ื•ืช ื”ื›ืจื•ืžื•ื–ื•ืžื™ื, ื›ืžื• ืงืฆื•ื•ืช ื”ืคืœืกื˜ื™ืง ืฉืœ ืฉืจื•ื›ื™ ื ืขืœื™ื™ื. ืžื ื™ืขืช ื”ืชืงืฆืจื•ืช ื”ื˜ืœื•ืžืจื™ื ืขื•ื–ืจืช ืœื”ืื˜ ืืช ืชื”ืœื™ืš ื”ื”ื–ื“ืงื ื•ืช. ื›ืœ ืฉื›ืคื•ืœ ืฉืœ ืชื ื’ื•ืจื ืœื”ืกืจืช ื—ืœืง ืžื”ื˜ืœื•ืžืจ, ืžื” ืฉืžื•ื‘ื™ืœ ืœื”ื–ื“ืงื ื•ืช ื”ืชืื™ื ื•ื‘ืกื•ืคื• ืฉืœ ื“ื‘ืจ ืœืžื•ื•ืช. ืžื—ืงืจื™ื ืื—ืจื™ื ื”ืจืื• ื›ื™ NAD ื™ื›ื•ืœ ืœื™ื™ืฆื‘ ืืช ืงืฆื•ื•ืช ื”ื˜ืœื•ืžืจื™ื ื•ืœืžื ื•ืข ืืช ืงื™ืฆื•ืจื.

ืฉื ื™ืช, ื ืจืื” ื›ื™ NAD ืžื’ื‘ื™ืจ ืืช ื”ืคืขื™ืœื•ืช ืฉืœ ืกื™ืจื˜ื•ึผืื™ื ื™ื. ืœืคื™ ืžื—ืงืจื™ื, ื–ื” ืžืื˜ ืืช ืชื”ืœื™ืš ื”ื”ื–ื“ืงื ื•ืช. ื”ืžื“ืขื ื™ื ืขื“ื™ื™ืŸ ื—ื•ืงืจื™ื ืืช ื”ืชื—ื•ื ื”ื—ื“ืฉื ื™ ื”ื–ื” ื›ื“ื™ ืœื”ื‘ื™ืŸ ืืช ื”ืžื ื’ื ื•ืŸ ืฉืœื• ื‘ื™ืชืจ ืคื™ืจื•ื˜.

2. ื‘ืจื™ืื•ืช ื”ืžื•ื—

ื›ื›ืœ ืฉืื ื• ืžื–ื“ืงื ื™ื, ื”ืžื•ื— ืฉืœื ื• ืžืื‘ื“ ืืช ื”ื—ื“ื•ืช ื”ืžื—ืฉื‘ืชื™ืช ืฉื”ื™ื™ืชื” ืœื ื• ื‘ื’ื™ืœ ืฆืขื™ืจ. ื”ื–ื“ืงื ื•ืช ื’ื•ืจืžืช ืœืคื’ื™ืขื” ื‘ื™ื›ื•ืœืช ื”ื”ื™ื–ื›ืจื•ืช ื•ื‘ืžื”ื™ืจื•ืช ืขื™ื‘ื•ื“ ื”ื ืชื•ื ื™ื ื‘ืžื•ื—. ืฉื™ืคื•ืจ ื‘ืžื“ื“ื™ื ื”ืœืœื• ืžื•ืขื™ืœ ืœื›ื•ืœื ื‘ืžื™ื“ื” ืžืฉืžืขื•ืชื™ืช, ื•ื™ืฉ ื—ืฉื™ื‘ื•ืช ืจื‘ื” ืœืžืฆื™ืืช ื“ืจื›ื™ื ืœืžื ื•ืข ืฉื™ื˜ื™ื•ืŸ ื•ืžื—ืœื•ืช ื ื•ื™ืจื•ืœื•ื’ื™ื•ืช ืื—ืจื•ืช.

ื ื™ืกื•ื™ื™ื ืงืœื™ื ื™ื™ื ืจื‘ื™ื ื’ื•ืจืกื™ื ื›ื™ NAD ืขืฉื•ื™ ืœืฉืคืจ ืืช ืขืงื•ืžืช ื”ืœืžื™ื“ื” ื•ืืช ื’ื™ื‘ื•ืฉ ื”ื–ื™ื›ืจื•ืŸ. NAD ืžืกื™ื™ืข ืœืชืงืŸ ื“ื "ื ืคื’ื•ื ื‘ืžื•ื— ื•ื‘ืชืื™ ืขืฆื‘ ืื—ืจื™ื. NAD ื’ื ืžืคืขื™ืœ ื—ืœื‘ื•ื ื™ื ืกืคืฆื™ืคื™ื™ื ืฉืžื’ื™ื ื™ื ืขืœ ื”ืžื•ื— ืžืคื ื™ ื ื–ืงื™ ื—ืžืฆื•ืŸ.

ื—ืฉื•ื‘ ืœืฆื™ื™ืŸ ื›ื™ ื”ืคื’ื™ืขื” ื”ื›ืจื•ื ื™ืช ื‘ื“ื "ื ื•ื‘ืชืื™ ื”ืขืฆื‘ ืžื’ื‘ื™ืจื” ืืช ื”ืกื™ื›ื•ืŸ ืœืžื—ืœื•ืช ื›ืžื• ืฉื™ื˜ื™ื•ืŸ, ืžื—ืœืช ืคืจืงื™ื ืกื•ืŸ ื•ืฉื™ื˜ื™ื•ืŸ ืขื ื’ื•ืคื™ืคื™ ืœื•ืื™.

ื ื•ืกืฃ ืขืœ ื›ืš, ืžื—ืงืจ ืžืฉื ืช 2021 ื”ืจืื” ื›ื™ ืชื•ืกืคื™ NAD ืขืฉื•ื™ื™ื ืœืกื™ื™ืข ื‘ืฉื™ืžื•ืจ ื”ืชืคืงื•ื“ ื”ืงื•ื’ื ื™ื˜ื™ื‘ื™ ื‘ืžื˜ื•ืคืœื™ื ืฉืžืงื‘ืœื™ื ื›ื™ืžื•ืชืจืคื™ื” ื ื’ื“ ืกืจื˜ืŸ. ื™ืชืจ ืขืœ ื›ืŸ, ืžื—ืงืจ ืžืฉื ืช 2023 ื”ืจืื” ื›ื™ ื™ืฉ ืœ-NAD ืชืจื•ืžื” ืžืจื›ื–ื™ืช ืœื‘ืจื™ืื•ืช ื”ืžื•ื— ืืฆืœ ื—ื•ืœื™ ืืœืฆื”ื™ื™ืžืจ.

ืœื‘ืกื•ืฃ, ืžื—ืงืจ ืฉื ืขืจืš ืœืื—ืจื•ื ื” ื’ื ื”ื“ื’ื™ื ืขื“ื•ื™ื•ืช ืœืฉื™ืคื•ืจ ื‘ื–ืจื™ืžืช ื”ื“ื ืœืžื•ื—, ื•ื–ื” ืขื•ื–ืจ ืœืžื˜ื‘ ืืช ื‘ืจื™ืื•ืช ื”ืžื•ื—.

3. ืžื™ื˜ื•ื‘ ืจืžื•ืช ื”ืกื•ื›ืจ ื‘ื“ื

ืชื ื’ื•ื“ืช ืœืื™ื ืกื•ืœื™ืŸ ื•ื˜ืจื•ื-ืกื•ื›ืจืช ื”ื ืชืกืžื™ื ื™ ื”ื–ื“ืงื ื•ืช ื ืคื•ืฆื™ื, ื•ื–ืืช ื”ืกื™ื‘ื” ืœื›ืš ืฉืกื•ื›ืจืช ืฉื›ื™ื—ื” ื™ื•ืชืจ ื‘ืงืจื‘ ืื ืฉื™ื ืžื‘ื•ื’ืจื™ื. ื’ื ืœืชื–ื•ื ื” ื™ืฉ ืชืคืงื™ื“ ืžืจื›ื–ื™ ื‘ื›ืš. ืœืžืจื‘ื” ื”ืžื–ืœ, ืžืกืคืจ ืžื—ืงืจื™ื ืชื•ืžื›ื™ื ื‘ื”ืฉืคืขืช NAD ืขืœ ื•ื™ืกื•ืช ื”ืจื’ื™ืฉื•ืช ืœืื™ื ืกื•ืœื™ืŸ. ื›ื›ืœ ืฉืื ื—ื ื• ืžืชื—ื™ืœื™ื ืœืฉื™ื ืœื‘ ืœืื•ืจื— ื”ื—ื™ื™ื ืฉืœื ื• ืžื•ืงื“ื ื™ื•ืชืจ, ื›ืš ื™ืฉ ืœื ื• ืกื™ื›ื•ื™ ื’ื‘ื•ื” ื™ื•ืชืจ ืœืžื ื•ืข ื”ืชืคืชื—ื•ืช ืฉืœ ืžื—ืœื•ืช ืžื–ื™ืงื•ืช ื›ืžื• ืกื•ื›ืจืช.

ืœื“ื•ื’ืžื”, ื”ื•ื“ื’ื ืฉื ื˜ื™ืœื” ืคื•ืžื™ืช ืฉืœ ืชื•ืกืฃ NAD ืžื‘ื™ืื” ืœืชื•ืฆืื•ืช ื—ื™ื•ื‘ื™ื•ืช ื‘ืื™ื–ื•ืŸ ืจืžื•ืช ื”ื’ืœื•ืงื•ื– ืืฆืœ ืขื›ื‘ืจื™ื ืขื ืกื•ื›ืจืช.  

ื™ืชืจ ืขืœ ื›ืŸ, ืžื—ืงืจ ืื—ืจ ื‘ื“ืง ืืช ื”ื™ืชืจื•ื ื•ืช ืฉืœ ื ื˜ื™ืœืช ืชื•ืกืฃ NAD ื‘ืžื™ื ื•ืŸ 250 ืž"ื’ ื‘ืžืฉืš ืขืฉืจื” ื™ืžื™ื ื‘ืงืจื‘ ื ืฉื™ื ืœืื—ืจ ื—ื™ื“ืœื•ืŸ ื•ืกืช. ื›ืœ ื”ื ื‘ื“ืงื•ืช ื”ื™ื• ืขื ื”ืฉืžื ืช ื™ืชืจ ื•ื˜ืจื•ื-ืกื•ื›ืจืช. ื”ืชื•ืฆืื•ืช ื”ืจืื• ืฉื”ื ื‘ื“ืงื•ืช ืฉื ื˜ืœื• ืชื•ืกืฃ NAD ื”ื“ื’ื™ืžื• ืฉื™ืคื•ืจ ื ื™ื›ืจ ื‘ืจื’ื™ืฉื•ืช ืœืื™ื ืกื•ืœื™ืŸ. ื”ื”ืฉืคืขื•ืช ื”ืœืœื• ืœื ื ืฆืคื• ื‘ืงื‘ื•ืฆืช ื”ื‘ื™ืงื•ืจืช. ื™ื™ืชื›ืŸ ืฉื™ืฉ ืœื›ืš ื—ืฉื™ื‘ื•ืช, ืฉื›ืŸ ืžืขืจื™ื›ื™ื ื›ื™ 1 ืžื›ืœ 3 ืื ืฉื™ื ื‘ืขื•ืœื ืกื•ื‘ืœ ืžืชื ื’ื•ื“ืช ืœืื™ื ืกื•ืœื™ืŸ ื•/ืื• ื˜ืจื•ื-ืกื•ื›ืจืช.

4. ื‘ืจื™ืื•ืช ื”ื›ืœื™ื•ืช

ืจื•ื‘ ื”ืื ืฉื™ื ื ื•ืœื“ื™ื ืขื ืฉืชื™ ื›ืœื™ื•ืช; ืชืคืงื™ื“ืŸ ื”ื•ื ืœืกื ืŸ ืจืขืœื ื™ื ืžื”ื’ื•ืฃ ื•ืœืกื™ื™ืข ื‘ืฉืžื™ืจื” ืขืœ ืžืื–ืŸ ื”ืืœืงื˜ืจื•ืœื™ื˜ื™ื ื‘ื’ื•ืฃ. ืœืขืชื™ื ืงืจื•ื‘ื•ืช ืชืจื•ืคื•ืช ืžืกื•ื™ืžื•ืช ื•ื”ื–ื“ืงื ื•ืช ืžืฉืคื™ืขื•ืช ืขืœ ื”ื›ืœื™ื•ืช ื•ืžื•ื‘ื™ืœื•ืช ืœืคื’ื™ืขื” ื‘ืกื™ื ื•ืŸ ื”ื›ืœื™ื™ืชื™ ื‘ืžื”ืœืš ื”ืฉื ื™ื.  

ืœืžืจื‘ื” ื”ืžื–ืœ, ื ืจืื” ื›ื™ NAD ืžื’ืŸ ืขืœ ืชืคืงื•ื“ ื”ื›ืœื™ื•ืช ื•ืžื•ื ืข ื ื–ืงื™ ื—ืžืฆื•ืŸ ืœื›ืœื™ื•ืช. ื—ื•ืงืจื™ื ืžืืžื™ื ื™ื ื›ื™ ื”ืกื’ื•ืœื•ืช ื”ืœืœื• ื ื•ื‘ืขื•ืช ืžื”ื”ืฉืคืขื” ืžืขื›ื‘ืช ื”ื”ื–ื“ืงื ื•ืช ื•ื ื•ื’ื“ืช ื”ื“ืœืงืช ืฉืœ NAD ื•-SIRT1.

5. ื‘ืจื™ืื•ืช ื”ืœื‘

ืžื—ืœื•ืช ืœื‘ ื”ืŸ ืื—ืช ืžื’ื•ืจืžื™ ื”ืžื•ื•ืช ื”ืžื•ื‘ื™ืœื™ื ื‘ื›ืœ ืจื—ื‘ื™ ื”ืขื•ืœื. ื”ืกื™ื›ื•ืŸ ืœืžื—ืœื•ืช ืœื‘ ื’ื•ื‘ืจ ื›ื›ืœ ืฉืื ื• ืžื–ื“ืงื ื™ื. ืžืฆื™ืืช ื“ืจื›ื™ื ืœืžื ื•ืข ืžื—ืœื•ืช ืœื‘ ื”ื•ื ื”ืžืคืชื— ืœืืจื™ื›ื•ืช ื™ืžื™ื.

ืœืคื™ ืžื—ืงืจื™ื, ื ืจืื” ื›ื™ NAD ืžื•ืขื™ืœ ืœืœื‘. ื‘ืคืจื˜, ืžื—ืงืจ ืžืฉื ืช 2018 ืžืฆื ื›ื™ NAD ื™ื›ื•ืœ ืœืฉืงื ืืช ื’ืžื™ืฉื•ืช ื›ืœื™ ื”ื“ื ื•ืœืžื ื•ืข ืคื’ื™ืขื” ื‘ืื ื“ื•ืชืœ (ื“ืคื ื•ืช ื”ืขื•ืจืงื™ื) โ€“ ื”ื˜ืจื™ื’ืจ ืœื›ืœ ื”ืžืงืจื™ื ืฉืœ ื—ืกื™ืžืช ืขื•ืจืงื™ื. ืื•ืชื• ื”ืžื—ืงืจ ืžืฆื ื’ื ื›ื™ NAD ืงื™ื“ื ื”ื™ื•ื•ืฆืจื•ืช ืฉืœ ื›ืœื™ ื“ื ื—ื“ืฉื™ื ื‘ืฉืจื™ืจื™ ื”ืฉืœื“ ืืฆืœ ืขื›ื‘ืจื™ื ืงืฉื™ืฉื™ื. ื›ืชื•ืฆืื” ืžื›ืš, ื”ืกื™ื‘ื•ืœืช ืฉืœื”ื ื ื”ื™ื™ืชื” ื‘ืช ื”ืฉื•ื•ืื” ืœื–ื• ืฉืœ ืขื›ื‘ืจื™ื ืฆืขื™ืจื™ื.

ื™ืชืจ ืขืœ ื›ืŸ, NAD ืžืฉืคืจ ืืช ื–ืจื™ืžืช ื”ื“ื, ื•ื ืจืื” ื’ื ืฉื™ืฉ ืœื• ืชืคืงื™ื“ ื‘ื˜ื™ืคื•ืœ ื‘ืื™-ืกืคื™ืงืช ืœื‘.

ื—ื•ืงืจื™ื ืžืฆืื• ื›ื™ ืกื™ืจื˜ื•ึผืื™ื ื™ื ืขืฉื•ื™ื™ื ืœืฉื ื•ืช ืืช ื—ื™ืœื•ืฃ ื”ื›ื•ืœืกื˜ืจื•ืœ ื‘ื’ื•ืฃ, ืชื”ืœื™ืš ืฉืžืชืจื—ืฉ ื›ืชื•ืฆืื” ืžื ื˜ื™ืœืช ืชื•ืกืคื™ NAD.

 6. ืชืกืžื•ื ืช ื”ืขื™ื™ืคื•ืช ื”ื›ืจื•ื ื™ืช

ืžื—ืงืจื™ื ืจื‘ื™ื ืขืกืงื• ื‘ื”ืฉืคืขืช NAD ืขืœ ืชืกืžื•ื ืช ื”ืขื™ื™ืคื•ืช ื”ื›ืจื•ื ื™ืช, ื”ืžื›ื•ื ื” ืœืคืขืžื™ื ื’ื ื‘ืฉื ืื ืฆืคืœื•-ืžื™ืืœื™ื˜ื™ืก ืžื™ืืœื’ื™ืช. ืžืืžื™ื ื™ื ื›ื™ ื”ืžื—ืœื” ื”ื–ื• ืžืชืจื—ืฉืช ื‘ื’ืœืœ ื™ืจื™ื“ื” ื‘ื™ื™ืฆื•ืจ ื”-ATP (ื”ืื ืจื’ื™ื”). ืื ืฉื™ื ืฉืกื•ื‘ืœื™ื ืžื”ืžื—ืœื” ื”ื–ื• ืชืžื™ื“ ืžืจื’ื™ืฉื™ื ืขื™ื™ืคื™ื, ื•ืœื ืžืฉื ื” ื›ืžื” ื”ื ื ื—ื™ื.

ืœื”ืœืŸ ืžืกืคืจ ืชืื•ืจื™ื•ืช ืฉื”ื•ืขืœื• ื‘ืชื•ืจ ื”ืกื‘ืจ ืืคืฉืจื™ ืœืชื•ืคืขื” ื”ื–ื•:

  • NAD ืžืžื˜ื‘ ืืช ื”ืชื”ืœื™ืš ืฉืœ ื”ืคื™ื›ืช ืžื–ื•ืŸ ืœืื ืจื’ื™ื”. ืฆื•ืจืช ื”ืื ืจื’ื™ื” ื”ืขื™ืงืจื™ืช ื‘ื” ื”ื’ื•ืฃ ืžืฉืชืžืฉ ื”ื™ื ืื“ื ื•ื–ื™ืŸ ื˜ืจื™-ืคื•ืกืคื˜ (ATP).
  • NAD ืžื’ื‘ื™ืจ ืืช ื”ื™ื™ืฆื•ืจ ืฉืœ ืžื•ืœื™ื›ื™ื ืขืฆื‘ื™ื™ื, ื”ื›ื™ืžื™ืงืœื™ื ื”ืื—ืจืื™ื ืœืชืงืฉื•ืจืช ื‘ื™ืŸ ืชืื™ ื”ืžื•ื—. ื“ื•ื’ืžืื•ืช ืœืžื•ืœื™ื›ื™ื ืขืฆื‘ื™ื™ื: ื“ื•ืคืžื™ืŸ, ืกืจื•ื˜ื•ื ื™ืŸ ื•ื ื•ืจืืคื™ื ืคืจื™ืŸ.

ื‘ืžื—ืงืจ ืžืฉื ืช 2015 ื”ื—ื•ืงืจื™ื ื’ื™ื™ืกื• 73 ื ืฉื™ื ืขื ืชืกืžื•ื ืช ื”ืขื™ื™ืคื•ืช ื”ื›ืจื•ื ื™ืช. ื›ื“ื™ ืœื—ืงื•ืจ ืืช ื”ื”ืฉืคืขื” ืฉืœ NAD ืขืœ ืชืกืžื•ื ืช ื”ืขื™ื™ืคื•ืช ื”ื›ืจื•ื ื™ืช, ื”ื—ื•ืงืจื™ื ืฉื™ืœื‘ื• ืชื•ืกืฃ NAD ืขื ืงื•-ืื ื–ื™ื {LRM}Q10 (ื’ื ื”ื•ื ื—ืฉื•ื‘ ืœื‘ืจื™ืื•ืช ื”ืžื™ื˜ื•ื›ื•ื ื“ืจื™ื”).

ื—ืœืง ืžื”ื ืฉื™ื ืฉื”ืฉืชืชืคื• ื‘ืžื—ืงืจ ืงื™ื‘ืœื• ืชื•ืกืฃ NAD ืขื ืงื•-ืื ื–ื™ื Q10. ื”ืื—ืจื•ืช ืงื™ื‘ืœื• ืคืœืฆื‘ื•. ืœืื—ืจ ื ื™ืชื•ื— ื”ืชื•ืฆืื•ืช, ื”ื—ื•ืงืจื™ื ื”ื‘ื—ื™ื ื• ื‘ืฉื™ืคื•ืจ ืžืฉืžืขื•ืชื™ ื‘ืชืคืงื•ื“ ื”ื’ื•ืคื ื™ ื•ื”ืงื•ื’ื ื™ื˜ื™ื‘ื™. ื‘ืจืžื” ื”ืžื•ืœืงื•ืœืจื™ืช, ืฉื™ืœื•ื‘ ืฉืœ NAD ืขื ืงื•-ืื ื–ื™ื Q10 ื”ื‘ื™ื ืœื”ื’ื‘ืจืช ืจืžื•ืช ื”-ATP (ื”ืื ืจื’ื™ื”).

ื“ื•ื— ืื—ืจ ืžืฆื ื›ื™ ื”ืฉื™ืœื•ื‘ ืฉืœ NAD ืขื ืงื•-ืื ื–ื™ื Q10 ื”ื‘ื™ื ืœื™ืจื™ื“ื” ื‘ืขื™ื™ืคื•ืช ืœืื—ืจ ืžืืžืฅ. ื”ืชืกืžื™ืŸ ื”ื–ื” ื”ื•ื ืชืกืžื™ืŸ ืื•ืคื™ื™ื ื™ ืฉืœ ืชืกืžื•ื ืช ื”ืขื™ื™ืคื•ืช ื”ื›ืจื•ื ื™ืช.

7. ื‘ื™ืฆื•ืขื™ื ืกืคื•ืจื˜ื™ื‘ื™ื™ื

ื”ืกืคื•ืจื˜ืื™ื ืชืžื™ื“ ืžื—ืคืฉื™ื ื“ืจื›ื™ื ืœืงื‘ืœ ื™ืชืจื•ืŸ ืชื—ืจื•ืชื™ ื‘ืฆื•ืจื” ื‘ื˜ื•ื—ื”. ื™ื™ืชื›ืŸ ืฉื›ื“ืื™ ืœืฉืงื•ืœ ืืช NAD ื‘ื”ืงืฉืจ ื–ื”. ืœื“ื•ื’ืžื”, ื ืขืจืš ืžื—ืงืจ ืฉื”ืชืžืงื“ ื‘ื”ืฉืคืขื” ืฉืœ ืชื•ืกืคื™ NAD ืขืœ ืืฆื ื™ื ื—ื•ื‘ื‘ื ื™ื. ื”ื—ื•ืงืจื™ื ื ืชื ื• ืœ-48 ืืฆื ื™ื ืชื•ืกืฃ NAD (ื‘ืžื™ื ื•ืŸ ืฉืœ 300, 600 ืื• 1200 ืž"ื’) ืื• ืคืœืฆื‘ื•. ืชื•ืกืฃ ื”-NAD ื ื™ืชืŸ ื‘ืžืฉืš ืฉื™ืฉื” ืฉื‘ื•ืขื•ืช. ื‘ืกื•ืฃ ื”ืžื—ืงืจ ื”ืืฆื ื™ื ืฉืงื™ื‘ืœื• NAD ื”ื“ื’ื™ืžื• ื›ื•ืฉืจ ืื™ืจื•ื‘ื™ ื’ื‘ื•ื” ื™ื•ืชืจ ื•ืขืœื™ื™ื” ื‘ื ื™ืฆื•ืœ ื”ื—ืžืฆืŸ ื‘ืฉืจื™ืจ ื‘ื”ืฉื•ื•ืื” ืœืงื‘ื•ืฆืช ื”ื‘ืงืจื”. ื ืจืื” ื›ื™ ืžื™ื ื•ื ื™ื ื’ื‘ื•ื”ื™ื ื™ื•ืชืจ ื”ื ื™ื‘ื• ืชื•ืฆืื•ืช ื˜ื•ื‘ื•ืช ื™ื•ืชืจ. ืœื ื ืฆืคื• ืชื•ืคืขื•ืช ืœื•ื•ืื™ ืžืกื•ื›ื ื•ืช. ืขื ื–ืืช, ื ื“ืจืฉื™ื ืžื—ืงืจื™ื ื ื•ืกืคื™ื ื‘ื ื•ืฉื ื–ื”.

ืชื•ืคืขื•ืช ืœื•ื•ืื™

ืชื•ืกืคื™ NAD ื ื—ืฉื‘ื™ื ื›ื‘ื˜ื•ื—ื™ื, ื›ืืฉืจ ื ื•ื˜ืœื™ื ืื•ืชื ื‘ืžื™ื ื•ื ื™ื ื”ืžื•ืžืœืฆื™ื. ืขื ื–ืืช, ื ื˜ื™ืœืช ืžื™ื ื•ื ื™ื ืžื•ืคืจื–ื™ื ืฉืœ NAD ืขืœื•ืœื” ืœื’ืจื•ื ืœื ื“ื•ื“ื™ ืฉื™ื ื”, ืœื—ืจื“ื” ื•ืœืจืขื“ ืฉืคื™ืจ. ื—ืฉื•ื‘ ืœื”ืงืคื™ื“ ืขืœ ื”ื”ื•ืจืื•ืช ื”ืžื•ืคื™ืขื•ืช ืขืœ ืชื•ื•ื™ืช ื”ืชื•ืกืฃ.

ืžื™ื ื•ื ื™ื ืžื•ืžืœืฆื™ื

ืื ื™ ืžืžืœื™ืฅ ืœื™ื˜ื•ืœ NAD, NMN ืื• NR ื•ืœื‘ื“ื•ืง ื›ืžื” ื”ื ื™ื•ืขื™ืœื• ืœื›ื, ืืœื ืื ืืชื ืจื•ื›ืฉื™ื ืชื•ืกืฃ ื”ืžื›ื™ืœ ืืช ื›ืœ ืฉืœื•ืฉืช ื”ืฆื•ืจื•ืช ืฉืœ NAD.

ื”ืžื™ื ื•ืŸ ื”ืžื•ืžืœืฅ ื‘ื ื˜ื™ืœืช{LRM} NAD ื”ื•ื ื‘ื“ืจืš ื›ืœืœ ื‘ื™ืŸ 100-300 ืž"ื’ ืฉืœ NAD ื‘ื™ื•ื.

ื”ืžื™ื ื•ืŸ ื”ืžื•ืžืœืฅ ื‘ื ื˜ื™ืœืช ืชื—ื™ืœืŸ ืฉืœ NAD, ื›ืžื• NR ืื• NMN, ื”ื•ื ื›ื“ืœืงืžืŸ: 300 ืž"ื’ ื‘ื™ื•ื ืฉืœ ื ื™ืงื•ื˜ื™ืŸ-ืืžื™ื“ ืจื™ื‘ื•ื–ื™ื“ (NR).

ื”ืžื™ื ื•ืŸ ื”ืžื•ืžืœืฅ ืขื‘ื•ืจ NMN ื”ื•ื ื‘ื™ืŸ 125 ืœ-300 ืž"ื’ ืฉืœ NMN ื‘ื™ื•ื.

ื”ืคื ื™ื•ืช:

  1. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021 Jun 11;372(6547):1224-1229.
  2. Uddin GM, Youngson NA, Doyle BM, Sinclair DA, Morris MJ. Nicotinamide mononucleotide (NMN) supplementation ameliorates the impact of maternal obesity in mice: comparison with exercise. Sci Rep. 2017 Nov 8;7(1):15063.
  3. Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018 Mar 6;27(3):529-547. doi: 10.1016/j.cmet.2018.02.011. PMID: 29514064; PMCID: PMC6342515.
  4. https://www.jstage.jst.go.jp/article/endocrj/67/2/67_EJ19-0313/_html/-char/en
  5. Mills K.F., Yoshida S., Stein L.R., Grozio A., Kubota S., Sasaki Y., Redpath P., Migaud M.E., Apte R.S., Uchida K., et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016;24:795โ€“806.
  6. https://www.harvardmagazine.com/2017/09/anti-aging-breakthrough
  7. Amano et al., 2019, Cell Metabolism 29, 1274โ€“1290
  8. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(19)30129-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1550413119301299%3Fshowall%3Dtrue
  9.  Guan Y, Wang SR, Huang XZ, Xie QH, Xu YY, Shang D, Hao CM. Nicotinamide Mononucleotide, an NAD+ Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1-Dependent Manner. J Am Soc Nephrol. 2017 Aug;28(8):2337-2352.
  10. Guan Y, Wang SR, Huang XZ, Xie QH, Xu YY, Shang D, Hao CM. Nicotinamide Mononucleotide, an NAD+ Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1-Dependent Manner. J Am Soc Nephrol. 2017 Aug;28(8):2337-2352
  11. Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021 Jul 8;18(1):54.
  12. Johnson S, Imai SI. NAD + biosynthesis, aging, and disease. F1000Res. 2018 Feb 1;7:132.
  13. Yoo KH, Tang JJ, Rashid MA, Cho CH, Corujo-Ramirez A, Choi J, Bae MG, Brogren D, Hawse JR, Hou X, Weroha SJ, Oliveros A, Kirkeby LA, Baur JA, Jang MH. Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. Cancer Res. 2021 Jul 1;81(13):3727-3737.
  14. Fang EF, Anisimov A. Turning up the NAD+-mitophagy axis to treat Alzheimer's disease. Neural Regen Res. 2023 Feb;18(2):319.
  15. https://www.sciencedirect.com/science/article/pii/S221323171930240X
  16. Karakelides H, Irving BA, Short KR, O'Brien P, Nair KS. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes. 2010 Jan;59(1):89-97.
  17. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011 Oct 5;14(4):528-36
  18. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021 Jun 11;372(6547):1224-1229.
  19. Tovar-Palacio C, Noriega LG, Mercado A. Potential of Polyphenols to Restore SIRT1 and NAD+ Metabolism in Renal Disease. Nutrients. 2022 Feb 3;14(3):653.
  20. Abdellatif M, Sedej S, Kroemer G. NAD+ Metabolism in Cardiac Health, Aging, and Disease. Circulation. 2021 Nov 30;144(22):1795-1817.
  21. Das A, Huang GX, Bonkowski MS, Longchamp A, Li C, Schultz MB, Kim LJ, Osborne B, Joshi S, Lu Y, Treviรฑo-Villarreal JH, Kang MJ, Hung TT, Lee B, Williams EO, Igarashi M, Mitchell JR, Wu LE, Turner N, Arany Z, Guarente L, Sinclair DA. Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging. Cell. 2018 Mar 22;173(1):74-89.e20.
  22. Lee CF, Chavez JD, Garcia-Menendez L, Choi Y, Roe ND, Chiao YA, Edgar JS, Goo YA, Goodlett DR, Bruce JE, Tian R. Normalization of NAD+ Redox Balance as a Therapy for Heart Failure. Circulation. 2016 Sep 20;134(12):883-94.
  23. Escande C, Nin V, Price NL, Capellini V, Gomes AP, Barbosa MT, O'Neil L, White TA, Sinclair DA, Chini EN. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2013 Apr;62(4):1084-93.
  24. https://www.liebertpub.com/doi/10.1089/ars.2014.6181
  25. https://www.cdc.gov/me-cfs/healthcare-providers/clinical-care-patients-mecfs/treating-most-disruptive-symptoms.html

โ€‹ื›ืชื‘ ื•ื™ืชื•ืจ:โ€‹ ืžืจื›ื– ื”ื‘ืจื™ืื•ืช ื”ื–ื” ืœื ื ื•ืขื“ ืœืื‘ื—ืŸ,,, โ€‹ื”ืฆื’ ืขื•ื“